Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 8/20 | 0.59 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | THRA | P10827 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.47 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.47 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL406107 | 0.87 | MAPT (0.59) | FFAR1ALDH1A1FFAR4LMNAS1PR2 | |
| SCHEMBL664336 | 0.86 | FFAR1 (0.61) | FFAR1KEAP1ALDH1A1NPSR1FFAR4 | |
| SCHEMBL28750453 | 0.85 | KEAP1 (0.55) | FFAR1KEAP1FFAR4THRATHRB | |
| Water SCHEMBL9330654 | 0.84 | FFAR1 (0.59) | FFAR1KEAP1ALDH1A1NPSR1CA1 | |
| SCHEMBL105022 | 0.84 | ALDH1A1 (0.58) | FFAR1ALDH1A1CA2THRATHRB | |
| SCHEMBL24723632 | 0.83 | FFAR1 (0.53) | FFAR1KEAP1ALDH1A1NPSR1FFAR4 | |
| SCHEMBL10485939 | 0.83 | FFAR1 (0.49) | FFAR1KEAP1ALDH1A1NPSR1FFAR4 | |
| SCHEMBL69746 | 0.82 | FFAR1 (0.81) | FFAR1KEAP1FFAR4CA1CA2 | |
| SCHEMBL11386630 | 0.81 | FFAR1 (0.47) | FFAR1KEAP1ALDH1A1NPSR1CA1 | |
| SCHEMBL24723497 | 0.81 | LMNA (0.69) | FFAR1FFAR4THRATHRBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | ONCOTHERAPY SCIENCE, INC. (JP) | 2012-03-08 | — | — | US | disclosed |
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | ONCOTHERAPY SCIENCE, INC. (JP) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | NR0B1, GRK7, NR5A2 | FFAR1 1729/4885KEAP1 994/4885ALDH1A1 3128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.